Compare Stocks: UMRX, DNTH, KNSA, and PTCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$115.96	$97.47	$19.84 ▼ $116.47	$6.34B	1.22	798,008 shs	903,313 shs
KNSA Kiniksa Pharmaceuticals International	$76.75	$64.42	$32.89 ▼ $82.94	$5.99B	0.05	695,096 shs	403,456 shs
PTCT PTC Therapeutics	$71.70	$77.79	$47.94 ▼ $90.87	$5.98B	0.56	1.21 million shs	564,330 shs
UMRX Cogent Biosciences	$36.95 +3.7%	$10.50	$0.29 ▼ $3.72	$1.57B	3.93	1.22 million shs	2.23 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	0.00%	+6.46%	+9.81%	+38.71%	+459.11%
KNSA Kiniksa Pharmaceuticals International	0.00%	+0.91%	+20.02%	+43.08%	+129.93%
PTCT PTC Therapeutics	0.00%	-2.20%	-8.77%	+2.21%	+46.87%
UMRX Cogent Biosciences	0.00%	0.00%	0.00%	0.00%	+210.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$115.96	$97.47	$19.84 ▼ $116.47	$6.34B	1.22	798,008 shs	903,313 shs
KNSA Kiniksa Pharmaceuticals International	$76.75	$64.42	$32.89 ▼ $82.94	$5.99B	0.05	695,096 shs	403,456 shs
PTCT PTC Therapeutics	$71.70	$77.79	$47.94 ▼ $90.87	$5.98B	0.56	1.21 million shs	564,330 shs
UMRX Cogent Biosciences	$36.95 +3.7%	$10.50	$0.29 ▼ $3.72	$1.57B	3.93	1.22 million shs	2.23 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	0.00%	+6.46%	+9.81%	+38.71%	+459.11%
KNSA Kiniksa Pharmaceuticals International	0.00%	+0.91%	+20.02%	+43.08%	+129.93%
PTCT PTC Therapeutics	0.00%	-2.20%	-8.77%	+2.21%	+46.87%
UMRX Cogent Biosciences	0.00%	0.00%	0.00%	0.00%	+210.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNTH Dianthus Therapeutics	2.93	Moderate Buy	$124.27	7.17% Upside
KNSA Kiniksa Pharmaceuticals International	2.80	Moderate Buy	$87.38	13.84% Upside
PTCT PTC Therapeutics	2.64	Moderate Buy	$98.55	37.44% Upside
UMRX Cogent Biosciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest UMRX, DNTH, KNSA, and PTCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$120.00 ➝ $122.00
8/13/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/13/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$106.00 ➝ $109.00
8/6/2026	DNTH Dianthus Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$110.00 ➝ $128.00
8/6/2026	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$130.00 ➝ $158.00
8/6/2026	PTCT PTC Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/5/2026	DNTH Dianthus Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$131.00
8/5/2026	DNTH Dianthus Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$105.00 ➝ $122.00
7/31/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/31/2026	PTCT PTC Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$93.00 ➝ $104.00
7/31/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$93.00 ➝ $106.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNTH Dianthus Therapeutics	$2.04M	3,107.61	N/A	N/A	$11.41 per share	10.16
KNSA Kiniksa Pharmaceuticals International	$677.56M	8.84	$0.79 per share	96.69	$7.44 per share	10.32
PTCT PTC Therapeutics	$1.01B	5.93	$8.78 per share	8.17	($2.56) per share	-28.01
UMRX Cogent Biosciences	$22.50M	69.74	N/A	N/A	$1.04 per share	35.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNTH Dianthus Therapeutics	-$162.34M	-$4.15	N/A	N/A	N/A	-10,096.95%	-22.53%	-21.55%	11/4/2026 (Estimated)
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	79.12	37.08	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	33.66	2.21	-3.80%	-362.45%	-1.32%	11/3/2026 (Estimated)
UMRX Cogent Biosciences	-$31.83M	-$1.04	N/A	N/A	N/A	-96.84%	-87.78%	-52.14%	N/A

Latest UMRX, DNTH, KNSA, and PTCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2026	Q2 2026	DNTH Dianthus Therapeutics	-$0.8463	-$0.90	-$0.0537	-$0.90	$0.30 million	$0.76 million
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNTH Dianthus Therapeutics	N/A	26.10	26.10
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49
PTCT PTC Therapeutics	N/A	3.39	3.28
UMRX Cogent Biosciences	0.18	2.90	2.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNTH Dianthus Therapeutics	47.53%
KNSA Kiniksa Pharmaceuticals International	53.95%
PTCT PTC Therapeutics	N/A
UMRX Cogent Biosciences	26.39%

Insider Ownership

Company	Insider Ownership
DNTH Dianthus Therapeutics	3.02%
KNSA Kiniksa Pharmaceuticals International	51.98%
PTCT PTC Therapeutics	5.30%
UMRX Cogent Biosciences	31.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNTH Dianthus Therapeutics	80	54.67 million	53.02 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	78.02 million	37.47 million	Optionable
PTCT PTC Therapeutics	1,410	83.46 million	79.04 million	Optionable
UMRX Cogent Biosciences	72	42.47 million	N/A	Not Optionable

UMRX, DNTH, KNSA, and PTCT Headlines

Recent News About These Companies

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

August 10, 2026 | markets.businessinsider.com

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 ...

May 30, 2026 | markets.businessinsider.com

Cogent Bio granted FDA priority review for lead asset in tumor indication

May 28, 2026 | seekingalpha.com

Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO ...

April 21, 2026 | markets.businessinsider.com

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

April 1, 2026 | markets.businessinsider.com

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

March 16, 2026 | markets.businessinsider.com

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough

February 17, 2026 | fool.com

Cogent Biosciences submits NDA for bezuclastinib in NONADVSM

December 30, 2025 | msn.com

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis

December 30, 2025 | tmcnet.com

Cogent Biosciences: Time For A Pause

December 15, 2025 | seekingalpha.com

Cogent Biosciences price target raised to $48 from $45 at Jefferies

December 8, 2025 | msn.com

Cogent Biosciences jumps after strong late-stage results in advanced systemic mastocytosis

December 8, 2025 | msn.com

Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

December 8, 2025 | markets.businessinsider.com

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American ...

December 6, 2025 | tmcnet.com

HC Wainwright & Co. Maintains Cogent Biosciences (COGT) Buy Recommendation

November 14, 2025 | msn.com

Cogent Biosciences price target raised to $50 from $21 at H.C. Wainwright

November 13, 2025 | msn.com

Cogent Biosciences’ phase 3 PEAK trial marks an advance in the treatment of gastrointestinal stromal tumors.

November 13, 2025 | managedhealthcareexecutive.comM

Cogent Biosciences’ phase 3 PEAK trial marks an advance in the treatment of gastrointestinal stromal tumors.

November 13, 2025 | managedhealthcareexecutive.comM

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes ...

November 11, 2025 | caledonianrecord.comC

Cogent Hits ‘Unprecedented’ Efficacy in Rare Stomach Cancer, Clearing Path to FDA

November 11, 2025 | biospace.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

UMRX, DNTH, KNSA, and PTCT Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

$115.96 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$118.85 +2.89 (+2.49%)

As of 08/14/2026 07:34 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$76.75 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$76.72 -0.03 (-0.05%)

As of 08/14/2026 07:34 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

PTC Therapeutics NASDAQ:PTCT

$71.70 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$71.69 -0.01 (-0.01%)

As of 08/14/2026 07:34 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Cogent Biosciences NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UMRX, DNTH, KNSA, and PTCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UMRX, DNTH, KNSA, and PTCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UMRX, DNTH, KNSA, and PTCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UMRX, DNTH, KNSA, and PTCT Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

Kiniksa Pharmaceuticals International NASDAQ:KNSA

PTC Therapeutics NASDAQ:PTCT

Cogent Biosciences NASDAQ:UMRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UMRX, DNTH, KNSA, and PTCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UMRX, DNTH, KNSA, and PTCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UMRX, DNTH, KNSA, and PTCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UMRX, DNTH, KNSA, and PTCT Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

Kiniksa Pharmaceuticals International NASDAQ:KNSA

PTC Therapeutics NASDAQ:PTCT

Cogent Biosciences NASDAQ:UMRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools